MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze INCY →
    • FindStock Picks / Stock Screener
    • Value · INCYIntrinsic Value Calculator
    • Invest · INCYInvestment Case
    • Hold · INCY5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
INCY stock logo

INCY

Incyte Corporation

$114.63
-1.25
 (-1.07%)
Exchange:  NASDAQ
Market Cap:  23.364B
Shares Outstanding:  195.204M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  William J. Meury
Full Time Employees:  2844
Address: 
1801 Augustine Cut-Off
Wilmington
DE
19803
US
Website:  https://www.incyte.com
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte’s pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation’s main offices are situated in Wilmington, Delaware.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ININCY logoINCYIncyte Corporation23.4B54.636.26.0%
UTUTHR logoUTHRUnited Therapeutics Corporation23.6B19.422.516.8%
BNBNTX logoBNTXBioNTech SE20.1B——-8.3%
ALALNY logoALNYAlnylam Pharmaceuticals, Inc.19.3B7.17.115.4%
ROROIV logoROIVRoivant Sciences Ltd.28.0B——-11.8%
ASASND logoASNDAscendis Pharma A/S16.6B16.215.411.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/29 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue3,695,6494,241,2175,141,242
Gross Profit3,440,6593,929,1174,769,142
EBITDA919,426408,1581,760,165
Operating Income655,358101,2941,342,790
Net Income597,59932,6151,286,650

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets6,782,1075,444,3226,957,973
Total Liabilities1,592,2701,996,6941,790,495
Total Stockholders Equity5,189,8373,447,6285,167,478
Total Debt38,28743,54434,715
Cash and Cash Equivalents3,213,3761,687,8293,097,817

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow496,487335,3371,413,498
Capital Expenditure-32,486-86,263-58,867
Free Cash Flow464,001249,0741,354,631
Net Income597,59932,6151,286,650
Net Change in Cash261,954-1,525,5471,409,988

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)5,065,409.464Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)5,650,233.060Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)5,337,159.423Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)1,432,140.635Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)1,631,075.399Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)1,524,579.950Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)844,057.903Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)972,816.988Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)903,888.580Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,429,830.298Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,594,910.437Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,506,538.080Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)4.500Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.850Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)4.210Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)10Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)5Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
4.241B  ?P/S
 (TTM)
: 
3.89
?Net Income
 (TTM)
: 
32.615M  ?P/E
 (TTM)
: 
54.58
?Enterprise Value
 (TTM)
: 
20.126B  ?EV/FCF
 (TTM)
: 
29.39
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
7.11%  ?ROIC
 (TTM)
: 
6.03%
?Net Debt
 (TTM)
: 
-2.098B  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
4.13  ?Current Ratio
 (TTM)
: 
3.84

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
36.16Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates INCY intrinsic value between $55.54 – $108.72 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate INCY Intrinsic Value

Common questions about INCY valuation

Is Incyte Corporation (INCY) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Incyte Corporation (INCY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is INCY a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether INCY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is INCY’s P/E ratio?

You can see INCY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for INCY?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is INCY a good long-term investment?

Whether INCY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Incyte Corporation

  • Incyte Corporation intrinsic value calculatorEstimate what the business is worth
  • Incyte Corporation 5-year outlookWhat has to go right, and what could go wrong
INCY

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.07
MarketSnap

Trading Metrics:

Open: 116.85   Previous Close: 115.87
Day Low: 114.3   Day High: 117.51
Year Low: 89.25   Year High: 132.6
Price Avg 50: 118.63   Price Avg 200: 109.25
Volume: 1.537M   Average Volume: 1.668M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loom
20-11-2026 21:13
Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loom
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
17-11-2026 13:53
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
Incyte says EU approves oral treatment for chronic skin disease
16-11-2026 16:54
Incyte says EU approves oral treatment for chronic skin disease
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
10-11-2026 13:00
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
What Incyte (INCY) Said on Its Q3 Earnings Call
29-10-2026 14:15
What Incyte (INCY) Said on Its Q3 Earnings Call
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
27-10-2026 04:49
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze INCY →
    • FindStock Picks / Stock Screener
    • Value · INCYIntrinsic Value Calculator
    • Invest · INCYInvestment Case
    • Hold · INCY5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.